Global Central Nervous System Drugs Market by Drug Classes (Analgesics, Anesthetics, Anti-Epileptics), Diseases (CNS Trauma, Infectious Diseases, Mental Health), Drug Type, Distribution Channel - Forecast 2024-2030

The Central Nervous System Drugs Market size was estimated at USD 20.71 billion in 2023, USD 22.44 billion in 2024, and is expected to grow at a CAGR of 9.85% to reach USD 39.99 billion by 2030.

Drugs for the Central nervous system (CNS) include sedatives, tranquilizers, and hypnotics for treating anxiety, panic, acute stress reactions, and sleep disorders. Central nervous system (CNS) drug companies have experienced extensive R&D efforts, which have resulted in the introduction of novel drug-delivery systems. The advancements in drug-delivery systems increase the adoption of novel drugs to treat central nervous system diseases. The increasing incidences of central nervous system disorders such as Alzheimer’s disease, epilepsy, Parkinson’s disease, multiple sclerosis, and stroke and the rising demand for effective drugs are raising the usage of CNS drugs. However, the requirement of high capital investment and adequate infrastructure for drug discovery and development, and stringent regulations for drug approvals are significantly impeding the adoption of CNS drugs. In addition, ongoing drug evolution and adoption of AI and ML in CNS drug discovery are increasing the utilization of CNS drugs.

Regional Insights

In the United States, pharmaceutical companies run awareness campaigns about diagnosing and treating CNS diseases and developing new drugs to increase the CNS drug rate. In May 2022, Minoryx Therapeutics, a Barcelona, Spain-based Phase 3 stage biotech company, focused on developing treatments for orphan central nervous system (CNS) disorders. In North America, the rising prevalence of neurological disorders, better reimbursement policies for treating CNS diseases, and increasing investments by companies to develop novel therapeutics have grown the utilization of CNS drugs. Rising approval of generic products owing to the patent expiration of key products, such as Copaxone and Invega, has increased the CNS treatment rate, especially in Asia-Pacifc. In Europe, the rising government investments in improving the healthcare infrastructure and the presence of huge numbers of patients with unfulfilled medical needs raised the usage of CNS drugs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Central Nervous System Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Central Nervous System Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Drugs Market, highlighting leading vendors and their innovative profiles. These include A. N. Pharmacia Laboratories Pvt. Ltd., AbbVie Inc., Alkermes PLC, Apotex Inc., Arvelle Therapeutics International GmbH by Angelini Pharma Inc., AstraZeneca PLC, Aurobindo Pharma, BIAL - PORTELA & CA, S.A., Biogen Inc., Catalent, Inc., CNS Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Divi's Laboratories Ltd., Dr. Reddy's Laboratories Ltd., East India Pharmaceutical Works Ltd., Eisai Co., Ltd., Eli Lilly and Company, Endo International PLC by DuPont de Nemours, Inc., Eridanus Healthcare, EVERSANA, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intas Pharmaceuticals Ltd., Jabs Biotech Pvt. Ltd., Johnson & Johnson Services, Inc., La Renon Healthcare Pvt. Ltd., Lupin Ltd., Merck & Co., Micro Labs Ltd., Midas Pharma GmbH, Neuracle Lifesciences Private Limited, Neurocon Inc., Novartis Group, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Priavoid GmbH, Reliance Formulations Pvt. Ltd., Sanofi S.A., Servier Laboratories (Aust) Pty Ltd, Shine Pharmaceuticals Ltd., Somacare, SteriMax Inc., Sun Pharmaceuticals Pvt Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., UCB S.A., Wellona Pharma, and Zee Laboratories Limited.

Market Segmentation & Coverage

This research report categorizes the Central Nervous System Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug Classes
  • Analgesics
  • Anesthetics
  • Anti-Epileptics
  • Anti-Parkinson Drugs
  • Antidepressant
• Diseases
  • CNS Trauma
  • Infectious Diseases
  • Mental Health
  • Neurodegenerative Diseases
  • Neurovascular Diseases
• Drug Type
  • Biologics
  • Non-Biologics
• Distribution Channel
  • Hospital Pharmacies
  • Online
  • Retail Pharmacies

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

1. What is the market size and forecast of the Central Nervous System Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Central Nervous System Drugs Market?
3. What are the technology trends and regulatory frameworks in the Central Nervous System Drugs Market?
4. What is the market share of the leading vendors in the Central Nervous System Drugs Market?
5. Which modes and strategic moves are suitable for entering the Central Nervous System Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.